The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 01, 2020

Filed:

Dec. 23, 2016
Applicants:

Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Lianyungang, Jiangsu, CN;

Shanghai Hansoh Biomedical Co., Ltd., Zhangjiang Hi-Tech Park, Shanghai, CN;

Inventors:

Zhongke Chen, Jiangsu, CN;

Fuping Liu, Jiangsu, CN;

Lei Liu, Jiangsu, CN;

Rudi Bao, Jiangsu, CN;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 403/04 (2006.01); A61K 31/506 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07D 403/04 (2013.01); A61P 35/00 (2018.01); C07B 2200/13 (2013.01);
Abstract

Disclosed are an EGFR inhibitor free base or acid salt polycrystalline form, a preparation method therefor, and an application thereof. The present invention specifically relates to an N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide free base or acid salt polycrystalline form, a preparation method therefor, and an application of the polycrystalline form in preparing a drug for treating an EGFR mutant activity-mediated disease. The present invention is used for inhibiting the activity of an L858R EGFR mutant, a T790M EGFR mutant and an exon 19 deletion activating mutant etc., may be widely applied in preventing and treating cancer, especially non-small cell lung cancer and other related diseases, and is expected to develop into a new generation of EGFR inhibitors.


Find Patent Forward Citations

Loading…